Using genetics to find targets for new drugs to treat relapsed neuroblastoma
Characterisation and validation of recurrently mutated genes in relapsed neuroblastoma as targets for novel therapies
Investigating a new approach to treating childhood brain tumours
Investigating the arginine auxotrophy of paediatric brain tumours
Understanding genetic changes in neuroblastoma cells to pave the way for targeted treatments
Investigation of the effects of DNA repair inhibitors in pre-clinical models of neuroblastomas with ATM, MYCN and TP53 abnormalities
Understanding what goes wrong in cells that leads to malignant rhabdoid tumours
Unravelling the impact of SMARCB1 loss on the chromatin landscape in malignant rhabdoid tumor to identify novel therapeutic opportunities
Helping to develop research into antibody treatment
Investigation of ganglioside-specific receptor expression by tumour-infiltrating immune cells
Repurposing mebendazole and albendazole for acute myeloid leukaemia
Testing the use of mebendazole and albendazole for children with acute myeloid leukaemia, and investigating how the drugs work.
Investigating a new way of delivery drugs to the site of childhood brain tumours
Brain distribution models to select polymer-delivered drugs for the treatment of childhood brain cancers
Developing a laboratory model of Wilms tumour to test potential new treatments
In vitro modelling of MYCN-driven poor prognosis Wilms' tumour for assessment of novel therapies
Developing a blood test to help identify high risk Wilms tumours
Circulating molecular biomarkers for earlier identification of high risk Wilms tumour